Described herein are methods and compositions for treating cancer. Aspects of the invention relate to determining if a biological sample obtained from a subject for GSK3a bodies (puncta), e.g., in response to asparaginase treatment, and administering to a subject having cancer an asparaginase and an agent that inhibits GSK3α to a subject who has been identified as forming GSK3α-positive bodies.

A novel prophylactic agent or therapeutic agent for functional gastrointestinal disorders or xerostomia is provided. The present invention is a therapeutic agent or prophylactic agent for functional gastrointestinal disorders, containing an azabenzimidazole compound represented by the following formula [1] (each symbol in the formula is as described in the specification), or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.

##STR00001##

A novel prophylactic agent or therapeutic agent for functional gastrointestinal disorders or xerostomia is provided. The present invention is a therapeutic agent or prophylactic agent for functional gastrointestinal disorders, containing an azabenzimidazole compound represented by the following formula [1] (each symbol in the formula is as described in the specification), or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.

##STR00001##

Compositions, methods and kits for treating active or passive titin-induced cardiac muscle stiffness by administering an HDAC6 specific inhibitor or an HDAC6 activator.

Compositions, methods and kits for treating active or passive titin-induced cardiac muscle stiffness by administering an HDAC6 specific inhibitor or an HDAC6 activator.

Disclosed herein are methods and compositions for inhibiting Aldh3a2 expression and activity to improve leukemia outcomes. Aldh3a2 depletion results in iron-dependent oxidative cell death of leukemia cells while sparing normal hematopoiesis.

Disclosed herein are methods and compositions for inhibiting Aldh3a2 expression and activity to improve leukemia outcomes. Aldh3a2 depletion results in iron-dependent oxidative cell death of leukemia cells while sparing normal hematopoiesis.

Disclosed herein are methods and compositions for inhibiting Aldh3a2 expression and activity to improve leukemia outcomes. Aldh3a2 depletion results in iron-dependent oxidative cell death of leukemia cells while sparing normal hematopoiesis.

The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.

The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.